1. Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study 
Samuel B. Foster, MD, Kenneth McIntosh, MD, Bruce Thompson, PhD, Ming Lu, MS, Wanrong Yin, MS, Kenneth C. Rich, MD, Hermann Mendez, MD, Leslie K. Serchuck, MD, Clemente Diaz, MD, Mary E. Paul, MD, William T. Shearer, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 122, Issue 1, Pages (July 2008)
DOI: /j.jaci
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Survival analysis results for the time to first asthma medication use. Cox model estimates relating differences between children according to HIV infection status and HAART use (in the HIV+ group) and respective P values are annotated in the lower right-hand portion of the graph. Estimated cumulative incidences for each group at 2, 5, 10, and 13.5 years of age are annotated in the upper left-hand portion of the graph.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Prevalence of asthma medication use for children born in the pre-HAART era using GEEs. Data are presented by using a 3-point moving average. No asthma medications were used by any group before 60 months.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Median CD4+ T-cell percentages in children aged 6 to 10 years indexed according to the time of first asthma medication use (Time 0). The slope estimates of CD4+ T cell percentages from the mixed-model analysis are annotated in the upper portion of the graph.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions